Interestingly, infection studies in A549 cell lines shows IFITM3 has greater antiviral activity against IAV and SARS-CoV-2 infection, whereas IFITM2 is more active against EBOV, that enter host cells through interactions with NPC1 in late endosomes59–61,65. This evidence concerns the gene NPC1 and infection.